Gordon Dunn - Jan 1, 2023 Form 3 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Role
Chief Financial Officer
Signature
/s/ Gordon Dunn
Stock symbol
QNRX
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
3
Date filed
1/3/2023, 08:40 AM
Next filing
Oct 30, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding QNRX Share Option (right to buy) Jan 1, 2023 Ordinary Shares 357M $0.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in four equal annual installments beginning on April 12, 2023.
F2 The number of securities underlying the option and the exercise price are listed in terms of ordinary shares, with five thousand (5,000) ordinary shares of the Issuer represented by one (1) American Depositary Share ("ADS"), which evidences the grant of an option to buy 71,428.56 ADSs at the exercise price of $17.50 per ADS.